Measles, Mumps, and Rubella (MMR) Immunity in College Students
This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine|
- Levels of mumps antibody and levels of memory B and T cell responses [ Time Frame: Day 1 for all participants except for those who receive MMR vaccine, there will be additional outcome measures on Day 0, 7, 14 and 28 post-vaccination. ] [ Designated as safety issue: No ]Cross sectional measurement of antibodies to mumps. measles or rubella
- Determine proportion of college-aged students who are seronegative for mumps [ Time Frame: outcome measurement on Day 1 ] [ Designated as safety issue: No ]Cross-sectional measurement of antibodies to mumps, measles and rubella
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2010|
|Study Completion Date:||December 2012|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
College-aged students who were immunized with MMR.
Biological: MMR vaccine
People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
Other Name: No other names
No additional description needed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00962819
|United States, Georgia|
|The Hope Clinic of the Emory Vaccine Center|
|Decatur, Georgia, United States, 30030|
|Principal Investigator:||Srilatha Edupuganti, MD||Emory University|